复发或难治性霍奇金淋巴瘤的治疗进展。
Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma.
机构信息
NYU Langone Hematology & Medical Oncology Fellowship Program, 550 First Avenue, New York, NY, 10016, USA.
Division of Hematology and Medical Oncology, Perlmutter Cancer Center at NYU Langone Health, New York University School of Medicine, Langone Medical Center, 240 East 38th Street, 19th Floor, New York, NY, 10016, USA.
出版信息
Curr Oncol Rep. 2020 Jan 24;22(1):6. doi: 10.1007/s11912-020-0866-3.
PURPOSE OF REVIEW
The landscape of relapsed or refractory (R/R) Hodgkin lymphoma (HL) treatment has changed significantly since the FDA approval of brentuximab vedotin in 2011. In this review, we summarize the recent advances in the therapy for R/R classical Hodgkin lymphoma (cHL).
RECENT FINDINGS
Immunotherapies with pembrolizumab, nivolumab, and ipilimumab, and chimeric antigen receptor (CAR) T cell therapies have shown promising results in early phase trials. Other novel agents under investigation include targeted therapies with histone deacetylase inhibitors, Janus kinase 2 inhibitors, and immunomodulators. While further studies with larger populations and longer follow-up times are needed to determine the safe and effective combinations, these novel approaches represent a growing list of treatment options that are on the horizon to improve the cure rate and increase duration of remission for R/R HL patients.
目的综述
自 2011 年 FDA 批准 Brentuximab vedotin 以来，复发或难治性（R/R）霍奇金淋巴瘤（HL）的治疗格局发生了重大变化。在这篇综述中，我们总结了 R/R 经典霍奇金淋巴瘤（cHL）治疗的最新进展。
最近的发现
免疫疗法药物 Pembrolizumab、Nivolumab 和 Ipilimumab，以及嵌合抗原受体（CAR）T 细胞疗法在早期试验中显示出有前景的结果。其他正在研究的新型药物包括组蛋白去乙酰化酶抑制剂、Janus 激酶 2 抑制剂和免疫调节剂的靶向治疗。虽然需要进一步的研究，包括更大的人群和更长的随访时间，以确定安全有效的联合治疗方案，但这些新方法代表了一系列不断增加的治疗选择，有望提高 R/R HL 患者的治愈率并延长缓解期。
Zotero 插件